Nanocomposite formulation system of lipid-regulating drugs based on layered double hydroxide: Synthesis, characterization and drug release properties

Mohamed R. Berber, Inas H. Hafez, Keiji Minagawa, Takeshi Mori, Masami Tanaka

研究成果: ジャーナルへの寄稿記事

17 引用 (Scopus)

抄録

Purpose: To design a nanocomposite formulation system of lipid-regulating drugs with versatile approaches using layered double hydroxide (LDH) material. Methods: The co-precipitation technique has been used to prepare the selected drugs [bezafibrate (BZF) and clofibric acid (CF)]-LDH nanocomposites. The nanocomposite materials (BZF-LDH and CF-LDH) were characterized by X-ray powder diffraction, infrared spectroscopy, thermogravimetric analysis, and scanning electron microscopy. The in vitro study was investigated in simulated gastrointestinal solutions at 36.8°C. Results: X-ray measurement and spectroscopic analysis indicated the formation of fully monophase drug-nanocomposites. The nanocomposites' gallery heights were calculated to be 23.5 and 16.3Å for BZF and CF, respectively. The new gallery heights indicated that BZF and CF drugs have been stacked into LDH as a monolayer with a staggered inter-digitated arrangement. The size of the nanocomposites described by SEM microscopy was ∼0.1 μm. The nanocomposite formulation has improved the drugs properties (thermal stability, dissolution, and controlled release) beside the achievement of drug target delivery. Conclusions: Nanocomposites composed of lipid-regulating drugs (BZF and CF) with LDH were successfully synthesized as a new formulation system of this drug category. The LDH nanocomposite formulation system has improved the drugs release properties.

元の言語英語
ページ(範囲)2394-2401
ページ数8
ジャーナルPharmaceutical Research
27
発行部数11
DOI
出版物ステータス出版済み - 11 1 2010

Fingerprint

Lipid Regulating Agents
Nanocomposites
Clofibric Acid
Bezafibrate
Pharmaceutical Preparations
Powder Diffraction
hydroxide ion
Drug Liberation
Drug Compounding
Scanning electron microscopy
Spectroscopic analysis
Coprecipitation
X-Ray Diffraction
Electron Scanning Microscopy
X ray powder diffraction
Thermogravimetric analysis
Microscopy
Infrared spectroscopy
Monolayers
Spectrum Analysis

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science
  • Organic Chemistry
  • Molecular Medicine
  • Pharmacology (medical)
  • Biotechnology
  • Pharmacology

これを引用

Nanocomposite formulation system of lipid-regulating drugs based on layered double hydroxide : Synthesis, characterization and drug release properties. / Berber, Mohamed R.; Hafez, Inas H.; Minagawa, Keiji; Mori, Takeshi; Tanaka, Masami.

:: Pharmaceutical Research, 巻 27, 番号 11, 01.11.2010, p. 2394-2401.

研究成果: ジャーナルへの寄稿記事

@article{192b1f3700064b1f86531e06c98d3c54,
title = "Nanocomposite formulation system of lipid-regulating drugs based on layered double hydroxide: Synthesis, characterization and drug release properties",
abstract = "Purpose: To design a nanocomposite formulation system of lipid-regulating drugs with versatile approaches using layered double hydroxide (LDH) material. Methods: The co-precipitation technique has been used to prepare the selected drugs [bezafibrate (BZF) and clofibric acid (CF)]-LDH nanocomposites. The nanocomposite materials (BZF-LDH and CF-LDH) were characterized by X-ray powder diffraction, infrared spectroscopy, thermogravimetric analysis, and scanning electron microscopy. The in vitro study was investigated in simulated gastrointestinal solutions at 36.8°C. Results: X-ray measurement and spectroscopic analysis indicated the formation of fully monophase drug-nanocomposites. The nanocomposites' gallery heights were calculated to be 23.5 and 16.3{\AA} for BZF and CF, respectively. The new gallery heights indicated that BZF and CF drugs have been stacked into LDH as a monolayer with a staggered inter-digitated arrangement. The size of the nanocomposites described by SEM microscopy was ∼0.1 μm. The nanocomposite formulation has improved the drugs properties (thermal stability, dissolution, and controlled release) beside the achievement of drug target delivery. Conclusions: Nanocomposites composed of lipid-regulating drugs (BZF and CF) with LDH were successfully synthesized as a new formulation system of this drug category. The LDH nanocomposite formulation system has improved the drugs release properties.",
author = "Berber, {Mohamed R.} and Hafez, {Inas H.} and Keiji Minagawa and Takeshi Mori and Masami Tanaka",
year = "2010",
month = "11",
day = "1",
doi = "10.1007/s11095-010-0175-x",
language = "English",
volume = "27",
pages = "2394--2401",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "11",

}

TY - JOUR

T1 - Nanocomposite formulation system of lipid-regulating drugs based on layered double hydroxide

T2 - Synthesis, characterization and drug release properties

AU - Berber, Mohamed R.

AU - Hafez, Inas H.

AU - Minagawa, Keiji

AU - Mori, Takeshi

AU - Tanaka, Masami

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Purpose: To design a nanocomposite formulation system of lipid-regulating drugs with versatile approaches using layered double hydroxide (LDH) material. Methods: The co-precipitation technique has been used to prepare the selected drugs [bezafibrate (BZF) and clofibric acid (CF)]-LDH nanocomposites. The nanocomposite materials (BZF-LDH and CF-LDH) were characterized by X-ray powder diffraction, infrared spectroscopy, thermogravimetric analysis, and scanning electron microscopy. The in vitro study was investigated in simulated gastrointestinal solutions at 36.8°C. Results: X-ray measurement and spectroscopic analysis indicated the formation of fully monophase drug-nanocomposites. The nanocomposites' gallery heights were calculated to be 23.5 and 16.3Å for BZF and CF, respectively. The new gallery heights indicated that BZF and CF drugs have been stacked into LDH as a monolayer with a staggered inter-digitated arrangement. The size of the nanocomposites described by SEM microscopy was ∼0.1 μm. The nanocomposite formulation has improved the drugs properties (thermal stability, dissolution, and controlled release) beside the achievement of drug target delivery. Conclusions: Nanocomposites composed of lipid-regulating drugs (BZF and CF) with LDH were successfully synthesized as a new formulation system of this drug category. The LDH nanocomposite formulation system has improved the drugs release properties.

AB - Purpose: To design a nanocomposite formulation system of lipid-regulating drugs with versatile approaches using layered double hydroxide (LDH) material. Methods: The co-precipitation technique has been used to prepare the selected drugs [bezafibrate (BZF) and clofibric acid (CF)]-LDH nanocomposites. The nanocomposite materials (BZF-LDH and CF-LDH) were characterized by X-ray powder diffraction, infrared spectroscopy, thermogravimetric analysis, and scanning electron microscopy. The in vitro study was investigated in simulated gastrointestinal solutions at 36.8°C. Results: X-ray measurement and spectroscopic analysis indicated the formation of fully monophase drug-nanocomposites. The nanocomposites' gallery heights were calculated to be 23.5 and 16.3Å for BZF and CF, respectively. The new gallery heights indicated that BZF and CF drugs have been stacked into LDH as a monolayer with a staggered inter-digitated arrangement. The size of the nanocomposites described by SEM microscopy was ∼0.1 μm. The nanocomposite formulation has improved the drugs properties (thermal stability, dissolution, and controlled release) beside the achievement of drug target delivery. Conclusions: Nanocomposites composed of lipid-regulating drugs (BZF and CF) with LDH were successfully synthesized as a new formulation system of this drug category. The LDH nanocomposite formulation system has improved the drugs release properties.

UR - http://www.scopus.com/inward/record.url?scp=78549278729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78549278729&partnerID=8YFLogxK

U2 - 10.1007/s11095-010-0175-x

DO - 10.1007/s11095-010-0175-x

M3 - Article

C2 - 20512405

AN - SCOPUS:78549278729

VL - 27

SP - 2394

EP - 2401

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 11

ER -